Evidence map›Paper›PMID 28915612›Full record

ArticleOncotarget2017

The roles of ING5 in gliomas: a good marker for tumorigenesis and a potential target for gene therapy.

Shuang Zhao, Zhi-Juan Zhao, Hao-Yu He, Ji-Cheng Wu, Xiao-Qing Ding, Lei Yang, Ning Jia, Zhi-Jie Li, Hua-Chuan Zheng

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. The roles of ING5 in cancer: A tumor suppressor.Frontiers in cell and developmental biology · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. NovelCancer genomics & proteomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Shuang ZhaoDepartment of Experimental Oncology and Animal Center, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Zhi-Juan ZhaoThe First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
Hao-Yu HeDepartment of Experimental Oncology and Animal Center, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Ji-Cheng WuDepartment of Experimental Oncology and Animal Center, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Xiao-Qing DingDepartment of Experimental Oncology and Animal Center, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Lei YangDepartment of Experimental Oncology and Animal Center, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Ning JiaThe First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
Zhi-Jie LiDepartment of Experimental Oncology and Animal Center, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Hua-Chuan ZhengDepartment of Experimental Oncology and Animal Center, Shengjing Hospital of China Medical University, Shenyang 110004, China.
China Medical University · CNJinzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To elucidate the anti-tumor effects and molecular mechanisms of ING5 on glioma cells, we overexpressed it in U87 cells, and examined the phenotypes and their relevant molecules. It was found that ING5 overexpression suppressed proliferation, energy metabolism, migration, invasion, and induced G

Indexed as

chemotherapygene therapygliomaING5tumorigenesis

Identifiers

PMID28915612
PMCPMC5593583
OpenAlexW2613819229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.